Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Dropping P2Y12 inhibitor from DAPT at 3 months post-stent safe in high bleeding-risk patients

Jairia Dela Cruz
08 Oct 2019
Dr Ajay Kirtane, director of Cardiac Catheterization Laboratories at Columbia University Irving Medical Center

Transitioning from dual antiplatelet therapy (DAPT) to aspirin monotherapy at 3 months following implantation of a thin-strut bioresorbable-polymer stent is safe for patients with high bleeding risk (HBR), according to the results of the EVOLVE Short DAPT trial presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Principal study investigator, Dr Ajay Kirtane, director of Cardiac Catheterization Laboratories at Columbia University Irving Medical Center/New York-Presbyterian Hospital, pointed out that the ischaemic outcomes in the 3–15 months following discontinuation of P2Y12 inhibitor were favourable.

Specifically, the coprimary endpoints of death or myocardial infarction (MI) and stent thrombosis with 3 months of DAPT were not inferior as compared with that achieved with a 12-month course.

EVOLVE Short DAPT included 2,009 HBR patients required to take aspirin plus P2Y12 inhibitor for 3 months after undergoing percutaneous coronary intervention. The study used Synergy, a stent that elutes everolimus from an ultrathin abluminal layer of a bioabsorbable polymer.

Of the patients, 1,487 (mean age, 75.7 years; 66 percent male) were eligible to discontinue P2Y12 inhibitor at 3 months but stay on aspirin between 3 and 15 months. All patients met at least one of the following criteria for HBR: age 75 years, a history of stroke, chronic anticoagulation, major bleeding within 12 months, and renal insufficiency or failure. Kirtane highlighted that the trial excluded patients with complex, high-risk stent-treated lesions.

The event rate for death or MI was 5.6 percent, while that for stent thrombosis was 0.3 percent. These numbers were noninferior relative to the corresponding 5.7 percent and 1.0 percent attained in the historical control group of propensity score-matched patients receiving 12-month DAPT (n=1,493; p=0.0016 and p<0.0001 for noninferiority, respectively). [Kirtane A, et al, TCT 2019]

Moreover, there was no marked difference in the rate of BARC 2/3/5 bleeding between the 3-month and the 12-month groups (6.26 percent vs 4.17 percent; p=0.98).

“These data prospectively demonstrate a low rate of adverse events for patients who are at high risk for bleeding and who then stop DAPT at 3 months,” supporting the use of Synergy with an abbreviated DAPT regimen, Kirtane said.

“This is critically important information because previously, the required duration of DAPT following implantation of current generation drug-eluting stent platforms was unknown. These data better inform physicians as to how best to tailor the recommended duration of DAPT to the bleeding risk of the patients they treat,” he added.

Kirtane, however, stressed that 3 months of DAPT should not be the be-all and end-all for patients treated with Synergy or some other stents, adding that what clinicians really need to know is the safe period to potentially stop if patients must indeed stop.

“There are many patients that have stents placed who need surgery or they have a gastrointestinal bleed and previously … people were really struggling with this in trying to keep people on DAPT up to 1 year because that’s what the guidelines had said,” he noted.

The takeaway is that EVOLVE Short DAPT and other recent studies supporting shorter poststent DAPT courses should provide reassurance that if DAPT has to be discontinued, “then patients are not going to thrombose their stents,” Kirtane explained. While it’s not true in all patients given the exclusion criteria, “it’s a good message for clinicians to have.”

In the ensuing discussion, the panellists were asked which antiplatelet should be dropped after 3 months. The answers varied, but none explicitly stated a preference for aspirin, in accordance with EVOLVE Short DAPT.

One panellist pointed out, “The benefits of aspirin were established in an era when many of the secondary prevention therapies that we have today were not available, like statins, ACE inhibitors, [among others].”

Another one noted a shifting view on aspirin: “We’ve moved from a time where taking away aspirin was thought to be sacrilegious, because it was largely based on belief over data, to an era where we can see taking away aspirin and going with a P2Y12 inhibitor.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.